Crossmark

Real-world efficacy of a teriparatide biosimilar (RGB-10) compared with reference teriparatide on bone mineral density, trabecular bone score, and bone parameters assessed using quantitative ultrasound, 3D-SHAPER® and high-resolution peripheral computer tomography in postmenopausal women with osteoporosis and very high fracture risk

Crossref DOI link: https://doi.org/10.1007/s00198-024-07208-z

Published Online: 2024-08-02

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hadji, Peyman https://orcid.org/0000-0003-4787-3151
Kamali, Luka

Thomasius, Friederike

Horas, Konstantin

Kurth, Andreas

Bock, Nina
Funding

Funding for this research was provided by:

STADA Arzneimittel AG

Philipps-Universität Marburg
License Information

Text and Data Mining valid from 2024-08-02

Version of Record valid from 2024-08-02
More Information

Article History

Received: 29 May 2024

Accepted: 22 July 2024

First Online: 2 August 2024

Declarations

:

: This study was performed in accordance with the Declaration of Helsinki as well as with local ethical requirements. All study subjects gave written consent to participate.

: P. Hadji: Has received study, educational and travel support from Amgen, Elli Lilly, Gedeon Richter, STADA Arzneimittel AG, Theramex and UCB. L. Kamali: No conflicts of interest relevant to this work. F. Thomasius: Has received honoraria for consulting or lectures from Amgen, Fresenius, Gedeon-Richter, STADA Arzneimittel AG, Theramex and UCB. K. Horas: No conflicts of interest relevant to this work. A. Kurth: Has received fees as a scientific advisor for Amgen, Theramex, Merit Medical, AgNovos, UCB, Image Biopsie Lab and as a lecturer for Amgen, STADA Arzneimittel AG, UCB, Alexion, AgNovos, Hologic. N. Bock: No conflicts of interest relevant to this work.

Document is current

Any future updates will be listed below